Nanjing Chia Tai Tianqing

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. was established in 2001, jointly invested by Thailand's Chia Tai and Jiangsu Agricultural Reclamation. It has two wholly-owned subsidiaries: Jiangsu Purun Biomedical Co., Ltd. (API platform) and Nanjing Chia Tai Weikang Biomedical Co., Ltd. (commercial platform). The company covers the full industrial chain of "drug R&D, APIs, preparations, and sales," with products spanning therapeutic areas such as cardiovascular and cerebrovascular diseases, oncology, surgical perioperative care, gastroenterology, urology, and contrast imaging. It has been ranked among the top 100 Chinese chemical pharmaceutical companies for many consecutive years. R&D is the foundation, and innovation drives progress. The company adheres to the R&D philosophy of "driving innovation through generics, and driving the future through innovation," relying on R&D investment several times the industry average and a team of hundreds of expert-level researchers, its R&D strength has ranked among the national forefront. Currently, it obtains approval for 5-8 new products annually, with over 100 products under development, covering innovative drugs, sustained and controlled-release preparations, and featured generics. The continuous operation of the postdoctoral workstation also injects sustained innovative vitality into the company's development. Marketing accelerates competitiveness. Since operation, the company's average annual compound growth rate of sales has reached 33%, far exceeding the industry average. It has formed a tiered product portfolio supported by hundred-million-yuan product groups, featuring "chronic diseases in the elderly and anti-tumor" therapies, with equal emphasis on oral and injectable formulations. The professional academic promotion team exceeds 2,000 people, covering three major scenarios: "hospitals, pharmacies, and the internet." Combined with a three-level academic promotion system led by medical science and anchored by the marketing system, its core products have achieved market leadership in segments such as cardiovascular and cerebrovascular diseases, oncology, surgical perioperative care, and imaging. Strength builds glory and witness. After 20 years of development, the company's "dual-engine drive of R&D and marketing" continues to accelerate. With the expansion of the industrial chain upstream to APIs and downstream to comprehensive disease management, coupled with the deep integration of scientific management and intelligent manufacturing, the company's healthy, sustainable, and rapid development is promoted. It has successively received honors such as "National Torch Plan Key High-tech Enterprise," "National Excellent Enterprise for Scientific and Technological Innovation," "National Demonstration Enterprise for Drug Quality and Integrity Construction," "Jiangsu Province May Day Labor Award," and "Jiangsu Province Demonstration Enterprise for Integration of Informatization and Industrialization." Facing the future, it writes a new chapter. As the company's strategic goal of "One Center, Three Platforms" (i.e., building an intensive strategic headquarters and developing three platforms: R&D and innovation, preparation intelligent manufacturing, and API intelligent efficiency) is gradually realized, along with the successive operation of its two subsidiaries, Nanjing Chia Tai Tianqing's full industrial chain layout continues to improve. In the future, through sustained efforts in core areas, it will benefit more patients, thereby practicing the business tenet of "Health for Humanity, Creating a Better Future Together"!